title: Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?
authors.affiliation: Cardiology Department, Papworth Hospital NHS Foundation Trust, Cambridge, UK. Electronic address: sergioncbarra@gmail.com.
authors.forename: Sergio
authors.initials: S
authors.lastname: Barra
authors.affiliation: Barts Heart Centre, Barts Health NHS Trust, London, UK.
authors.forename: Rui
authors.initials: R
authors.lastname: Providencia
authors.affiliation: Cardiology Department, Papworth Hospital NHS Foundation Trust, Cambridge, UK.
authors.forename: Sharad
authors.initials: S
authors.lastname: Agarwal
mesh_terms: D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data*; D006333:Heart Failure / Q000145:classification / Q000150:complications / Q000628:therapy*; D006801:Humans; D011322:Primary Prevention / Q000295:instrumentation*; D016896:Treatment Outcome
keywords: All-cause mortality; Cost-effectiveness; Heart failure; Implantable cardioverter-defibrillator; New York Heart Association; Number needed to treat